Format
Sort by

Send to

Choose Destination

Links from PubMed

Items: 1 to 20 of 86

1.

Human papillomavirus (HPV) vaccine policy and evidence-based medicine: are they at odds?

Tomljenovic L, Shaw CA.

Ann Med. 2013 Mar;45(2):182-93. doi: 10.3109/07853890.2011.645353. Review.

PMID:
22188159
2.

Human papillomavirus (HPV) vaccine policy and evidence-based medicine: are they at odds?

Fastrez M, Naik HN, Corfers A, Rozenberg S.

Ann Med. 2012 Jun;44(4):404. doi: 10.3109/07853890.2012.671539. No abstract available.

PMID:
22462602
3.

Efficacy and other milestones for human papillomavirus vaccine introduction.

Pagliusi SR, Teresa Aguado M.

Vaccine. 2004 Dec 16;23(5):569-78. Review.

PMID:
15630792
4.

The impact of anti HPV vaccination on cervical cancer incidence and HPV induced cervical lesions: consequences for clinical management.

Brinkman JA, Caffrey AS, Muderspach LI, Roman LD, Kast WM.

Eur J Gynaecol Oncol. 2005;26(2):129-42. Review.

PMID:
15857016
5.

Human Pappilomavirus (HPV) induced cancers and prevention by immunization.

Khaliq SA, Shyum Naqvi SB, Fatima A.

Pak J Pharm Sci. 2012 Oct;25(4):763-72.

PMID:
23009992
6.
7.

Vaccines against human papillomavirus and cervical cancer: promises and challenges.

Mahdavi A, Monk BJ.

Oncologist. 2005 Aug;10(7):528-38. Review.

9.

[Human papillomavirus prophylactic vaccines: stakes and perspectives].

Hantz S, Alain S, Denis F.

Gynecol Obstet Fertil. 2006 Jul-Aug;34(7-8):647-55. Review. French.

PMID:
16807045
10.

[Cervical cancer prevention: the impact of HPV vaccination].

Monsonégo J.

Gynecol Obstet Fertil. 2006 Mar;34(3):189-201. Review. French.

PMID:
16529969
12.

Implementation of human papillomavirus immunization in the developing world.

Kane MA, Serrano B, de Sanjosé S, Wittet S.

Vaccine. 2012 Nov 20;30 Suppl 5:F192-200. doi: 10.1016/j.vaccine.2012.06.075. Review.

PMID:
23199963
13.

Preventive and therapeutic HPV vaccines.

Monie A, Hung CF, Wu TC.

Curr Opin Investig Drugs. 2007 Dec;8(12):1038-50. Review.

PMID:
18058574
14.

Safety and immunogenicity of TA-HPV, a recombinant vaccinia virus expressing modified human papillomavirus (HPV)-16 and HPV-18 E6 and E7 genes, in women with progressive cervical cancer.

Kaufmann AM, Stern PL, Rankin EM, Sommer H, Nuessler V, Schneider A, Adams M, Onon TS, Bauknecht T, Wagner U, Kroon K, Hickling J, Boswell CM, Stacey SN, Kitchener HC, Gillard J, Wanders J, Roberts JS, Zwierzina H.

Clin Cancer Res. 2002 Dec;8(12):3676-85.

15.

Education about human papillomavirus and human papillomavirus vaccines in adolescents.

Kollar LM, Kahn JA.

Curr Opin Obstet Gynecol. 2008 Oct;20(5):479-83. doi: 10.1097/GCO.0b013e32830d0cf6. Review.

PMID:
18797272
16.

Planning for the HPV vaccine and its impact on cervical cancer prevention.

Bailey J, Cymet TC.

Compr Ther. 2006 Summer;32(2):102-5.

PMID:
16845153
17.

Vaccination against human papillomavirus.

BMJ Group..

Drug Ther Bull. 2008 Dec;46(12):89-93. Review.

PMID:
19056700
18.

Introducing human papillomavirus vaccines - questions remain.

Paavonen J, Lehtinen M.

Ann Med. 2008;40(3):162-6. doi: 10.1080/07853890701802404. Review.

PMID:
18382882
19.

Cervical cancer and HPV vaccines in developing countries.

Karimi Zarchi M, Behtash N, Chiti Z, Kargar S.

Asian Pac J Cancer Prev. 2009;10(6):969-74. Review.

20.

Immunogenicity and safety of human papillomavirus-16/18 AS04-adjuvanted cervical cancer vaccine in healthy Indian women.

Bhatla N, Suri V, Basu P, Shastri S, Datta SK, Bi D, Descamps DJ, Bock HL; Indian HPV Vaccine Study Group..

J Obstet Gynaecol Res. 2010 Feb;36(1):123-32. doi: 10.1111/j.1447-0756.2009.01167.x. Erratum in: J Obstet Gynaecol Res. 2010 Apr;36(2):466.

PMID:
20178538
Items per page

Supplemental Content

Support Center